Gain Therapeutics (GANX) Change in Acquisitions & Divestments (2022 - 2024)

Gain Therapeutics' Change in Acquisitions & Divestments history runs 3 years deep, the most recent figure standing at -$42502.0 for Q4 2024.

• In Q4 2024, Change in Acquisitions & Divestments fell 101.35% year-over-year to -$42502.0; the TTM figure through Dec 2024 stood at $5.0 million (down 59.0% YoY), while the FY2024 annual figure was $5.0 million, down 59.0% from the prior year.
• Change in Acquisitions & Divestments for Q4 2024 stood at -$42502.0, down from $2.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $4.1 million in Q1 2023, with the low at -$42502.0 in Q4 2024.
• The 3-year median for Change in Acquisitions & Divestments is $2.5 million (2022), against an average of $2.4 million.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments soared 51.45% in 2023, then sank 101.35% in 2024.
• Gain Therapeutics' Change in Acquisitions & Divestments stood at $2.1 million in 2022, then soared by 51.45% to $3.1 million in 2023, then sank by 101.35% to -$42502.0 in 2024.
• Business Quant data shows GANX's Change in Acquisitions & Divestments at -$42502.0 in Q4 2024, $2.0 million in Q2 2024, and $3.0 million in Q1 2024.